These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31039222)

  • 21. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.
    Johnson DA; Katz PO; Armstrong D; Cohen H; Delaney BC; Howden CW; Katelaris P; Tutuian RI; Castell DO
    Drugs; 2017 Apr; 77(5):547-561. PubMed ID: 28233274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.
    Raghunath AS; Hungin AP; Mason J; Jackson W
    Aliment Pharmacol Ther; 2009 Feb; 29(4):431-9. PubMed ID: 19035981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Step-by-step management of refractory gastresophageal reflux disease.
    Hershcovici T; Fass R
    Dis Esophagus; 2013 Jan; 26(1):27-36. PubMed ID: 22309405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The possible risks of proton pump inhibitors.
    Gracie DJ; Ford AC
    Med J Aust; 2016 Oct; 205(7):292-3. PubMed ID: 27681962
    [No Abstract]   [Full Text] [Related]  

  • 29. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies.
    El-Serag H; Becher A; Jones R
    Aliment Pharmacol Ther; 2010 Sep; 32(6):720-37. PubMed ID: 20662774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough.
    Kiljander TO
    Am J Med; 2003 Aug; 115 Suppl 3A():65S-71S. PubMed ID: 12928078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acid inhibition and infections outside the gastrointestinal tract.
    Vakil N
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S17-20. PubMed ID: 19262541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Reasons for proton-pump-inhibitor failure in the treatment of gastroesophageal reflux disease].
    Juhász M; Tulassay Z
    Orv Hetil; 2008 Oct; 149(40):1881-8. PubMed ID: 18815107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPI therapy: when to worry about fracture risk.
    Heidelbaugh JJ
    J Fam Pract; 2011 May; 60(5):255-60. PubMed ID: 21544271
    [No Abstract]   [Full Text] [Related]  

  • 35. Proton pump inhibitor use in infants: FDA reviewer experience.
    Chen IL; Gao WY; Johnson AP; Niak A; Troiani J; Korvick J; Snow N; Estes K; Taylor A; Griebel D
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):8-14. PubMed ID: 21946832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential adverse effects of proton pump inhibitors.
    Coté GA; Howden CW
    Curr Gastroenterol Rep; 2008 Jun; 10(3):208-14. PubMed ID: 18625128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of long-term PPI therapy.
    Reimer C
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):443-54. PubMed ID: 23998981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.
    Richter JE; Kumar A; Lipka S; Miladinovic B; Velanovich V
    Gastroenterology; 2018 Apr; 154(5):1298-1308.e7. PubMed ID: 29305934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroesophageal Reflux Disease.
    Kellerman R; Kintanar T
    Prim Care; 2017 Dec; 44(4):561-573. PubMed ID: 29132520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.